China-based drug maker Henlius has announced that the European Medicines Agency (EMA) has accepted for review the company’s marketing authorization application for a trastuzumab biosimilar, HLX02, referencing Herceptin.
China-based drug maker Henlius has announced that the European Medicines Agency (EMA) has accepted for review the company’s marketing authorization application (MMA) for a trastuzumab biosimilar, HLX02, referencing Herceptin.
"We are very pleased to receive the EMA acceptance to review of our trastuzumab biosimilar HLX02 MAA submission," Scott Liu, PhD, cofounder, president, and chief executive officer at Henlius, said in a statement announcing the application. "It shows that our clinical, medical, regulatory affairs and quality system capabilities have been internationally recognized. We plan to work closely with EMA on this HLX02 MAA and hope to benefit [HER2-positive] cancer patients globally with its high quality and affordability."
Last year, during the European Society for Medical Oncology’s 2018 annual meeting, Henlius reported on the clinical program for the biosimilar.1 The drug maker indicated that it had enrolled 12 healthy male volunteers to evaluate the safety and tolerability of a single infusion of the biosimilar at 2, 4, 6, and 8 mg/kg. The different concentrations demonstrated acute and dose-dependent effects on serum concentration.
A subsequent demonstration of safety and pharmacokinetic equivalence of the biosimilar and its US- and EU-licensed reference products was conducted in 109 healthy male volunteers. No deaths, serious adverse events, or antidrug antibodies were observed in any of the groups.
Finally, a phase 3 study was conducted in 649 patients with previously untreated HER2-positive metastatic breast cancer at centers in China, Ukraine, Poland, and the Philippines.
Henlius’ biosimilar trastuzumab is also under review by authorities at the National Medical Products Administration in China, which recently approved another Henlius biosimilar, HLX01, a rituximab product.
If approved, HLX02 would join a growing number of biosimilar options referencing Herceptin: Currently approved in the European Union are Trazimera, Ogivri, Ontruzant, Herzuma, and Kanjinti.
Reference
1. Zhang Q, Xu B, Zhang Q, et al. Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar. Presented at: European Society for Medical Oncology Asia 2018 Congress; November 23-25, 2018; Singapore. Abstract 44P.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.